Other inhibitors of kinases affecting the AKT/NFκB pathway, like the PI3Kδ inhibitor Idelalisib and the BTK inhibitor Ibrutinib, have recently shown a potent effect in disturbing the homing of CLL cells, each by different mechanisms [67,68], causing their mobilization from secondary lymphoid organs. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.